WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
New deal strengthens Congenica’s presence in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
